Showing results (1-10 of 8) with videos related to
Sort By:
Pageof 1
Clinical Lymphoma & Myeloma|October 10, 2006
Scleritis complicating zoledronic acid infusionDavid Benderson, Joyson Karakunnel, Sajeev Kathuria, et al.Investigational New Drugs|December 21, 2018
Safety, tolerability, and pharmacology of AB928, a novel dual adenosine receptor antagonist, in a randomized, phase 1 study in healthy volunteersLisa Seitz, Lixia Jin, Manmohan Leleti, et al.Plos One|August 4, 2017
Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumorsKathryn C Arbour, Jarushka Naidoo, Keith E Steele, et al.Journal for Immunotherapy of Cancer|August 24, 2019
Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignanciesAung Naing, Jeffrey Infante, Sanjay Goel, et al.Journal for Immunotherapy of Cancer|January 25, 2022
Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analysesClaire F Friedman, Christine Spencer, Christopher R Cabanski, et al.Critical Care Medicine|October 11, 2022
Avdoralimab (Anti-C5aR1 mAb) Versus Placebo in Patients With Severe COVID-19: Results From a Randomized Controlled Trial (FOR COVID Elimination [FORCE])Julien Carvelli, Ferhat Meziani, Jean Dellamonica, et al.The Lancet. Oncology|January 2, 2021
CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b studyMark H O'Hara, Eileen M O'Reilly, Gauri Varadhachary, et al.Nature Medicine|June 6, 2022
Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trialLacey J Padrón, Deena M Maurer, Mark H O'Hara, et al.Pageof 1